IRONWOOD PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Per Basic Share
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Income (Loss) from Continuing Operations, Per Basic Share of $3.26 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2022-02-18
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2020-09-30 was $0.22, a 69.23% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2019-12-31 was $0.31.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2019-09-30 was $0.13.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2019-06-30 was $0.08.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2021 was $3.26, a 386.57% increase from fiscal 2020.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2020 was $0.67, a 76.32% increase from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2019 was $0.38.
- IRONWOOD PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2018 was -$1.27.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2021-12-31 | $3.26 10-K · filed 2022-02-18 | |||
| 2020-12-31 | $0.67 10-K · filed 2022-02-18 | |||
| 2020-09-30 | $0.22 10-Q · filed 2020-11-05 | $0.40 10-Q · filed 2020-11-05 | ||
| 2019-12-31 | $0.31 10-K · filed 2021-02-17 | $0.38 10-K · filed 2022-02-18 | ||
| 2019-09-30 | $0.13 10-K · filed 2021-02-17 | $0.07 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.08 10-K · filed 2021-02-17 | |||
| 2019-03-31 | -$0.14 10-K · filed 2021-02-17 | |||
| 2018-12-31 | -$1.27 10-K · filed 2021-02-17 | |||
| 2011-06-30 | -$0.19 10-Q · filed 2011-08-12 | -$0.37 10-Q · filed 2011-08-12 | ||
| 2010-06-30 | -$0.18 10-Q · filed 2011-08-12 | -$0.39 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |